

# Genitourinary Committee

## Leadership

Chair: ..... Seth P. Lerner, MD  
 Vice-Chair: ..... Daniel P. Petrylak, MD  
 Executive Officer: ..... Christopher W. Ryan, MD  
 Statisticians: ..... Cathy M. Tangen, DrPH  
 ..... Melissa Plets, MS  
 ..... Sam Callis, MS

## Scientific Leadership

Translational Medicine: ..... David J. McConkey, PhD (GU Chair)  
 ..... Joshua J. Meeks, MD, PhD (Bladder)  
 ..... Amir Goldkorn, MD (Prostate)  
 ..... Sumanta "Monty" K. Pal, MD (Renal)  
 Radiation Oncology: ..... James B. Yu, MD  
 ..... Daniel A. Hamstra, MD  
 Imaging: ..... Evan Y. Yu, MD  
 ..... Hiram Shaish, MD  
 ..... John D. Hazle, PhD  
 Immunotherapeutics: ..... Shuchi Gulati, MD  
 Pathology: ..... M. Scott Lucia, MD  
 Surgery: ..... Kelly L. Stratton, MD  
 Early Therapeutics: ..... Neeraj Agarwal, MD  
 Bladder Organ Site Chairs: ..... Seth P. Lerner, MD (Localized)  
 ..... Thomas W. Flaig, MD (Advanced)  
 ..... Daniel P. Petrylak, MD (Advanced)  
 Prostate Organ Site Chairs: ..... Daniel W. Lin, MD (Localized)  
 ..... Tanya B. Dorff, MD (Advanced)  
 Renal Organ Site Chairs: ..... Brian Shuch, MD (Localized)  
 ..... Ulka N. Vaishampayan, MD (Advanced)

## Designates

Cancer Control: ..... Peter J. Van Veldhuizen, Jr., MD  
 DEI Champion: ..... Jessica D. McDermott, MD  
 Digital Engagement: ..... Neema Navai, MD  
 Veterans Affairs: ..... Michael M. Goodman, MD  
 Data Coordinators: ..... Jeri Jardine, BA  
 ..... Laura Wells, BA  
 ..... Michele Counts, BS  
 ..... Tonya Johnson, BS  
 Oncology Research Professionals:  
 CRAs: ..... Abigail L. Cornette, MS  
 ..... Cheryl Farlow, RN, OCN  
 Nurse: ..... Cheryl Kefauver, RN  
 Patient Advocates: ..... Rick Bangs, MBA (Emeritus)  
 ..... Darrell Nakagawa (Bladder)  
 ..... Tony Crispino (Emeritus)  
 ..... Karen Costello, MSS, LSW (Prostate)  
 ..... Laura B. Esfeller, MA (Renal)

Pharmaceutical Science: ..... Joyce Lee, PharmD  
 ..... Allison Schepers, PharmD  
 Protocol Project Manager: ..... Megan Keim  
 Clinical Trials Program Manager: ..... Mariah Norman, MS

## Time/Location

Saturday, October 14, 2023 10:15 a.m. - 12:15 p.m.  
 Room: Regency A (Ballroom Level, West Tower)

## Agenda

10:15 - 10:30 am: Chair's Welcome and Opening Remarks  
 Seth Lerner (by Zoom)  
 10:30 - 11:15 am: Cancer Control - Dr. Peter Van Veldhuizen  
 11:15 - 12:15 pm: Review of open approved trials - all organ site chairs

## Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak  
 Daneshmand (Local).

## Priority Study

**S2011**, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Temporary Closure: 7/11/23.

## Concepts in Development

**XXXX**, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (PRESERVE)." Dr. L. Ballas. Submitted to GU Bladder Task Force 2/21/23.

## Active Studies

**S1937**, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23.

**S1806**, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19.

# Genitourinary Committee

**CTSUA031701**, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

**CTSUA031803**, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

**CTSEAE8185**, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

**CTSEAE8192**, "A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy" Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

## Closed Studies

**S1011**, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

**S1602**, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

**S1605**, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

## Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

## Priority Study

**S1931**, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

## Concepts in Development

**XXXXX**, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. Resubmitted to GU Renal Task Force 7/12/23 for 7/26/23 review.

## Active Studies

**S2200**, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)" Drs. B. Maughan and S. Pal. Activated 9/19/22.

**CTSUAREN1721**, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

**CTSU/A031704**, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

**CTSU/A031801**, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19.

**CTSU/A031901**, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20.

## Closed Studies

**S1500**, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

**S0931**, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

# Genitourinary Committee

**CTSU/E2810**, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

**CTSU/A031501**, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

**CTSU/EA8143**, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

## Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

### Priority Study

**S2210**, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14.

### Concepts in Development

**S2312**, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Submitted to GUSC to address Round 2 of comments 9/6/23.

### Active Studies

**S1802**, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

**CTSU/A031102**, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

**CTSU/EA8171**, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

**CTSU/EA8184**, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

**CTSU/NRG-GU002**, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

**CTSU/NRG-GU008**, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE\*) \*Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

**CTSU/NRG-GU009**, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT\*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

### Closed Studies

**S1216**, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

**CTSU/NRG-GU005**, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

**CTSU/NRG-GU006**, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

**CTSU/RTOG-0924**, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial." Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

**CTSU/NRG-GU007**, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR\*) \*Randomized

# Genitourinary Committee

Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I).” Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11//2022.

**CTSU/EA8153**, “Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial.” Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

**CTSU/AGCT1531**, “A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.” Dr. A. D’Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

## Translational Medicine

Chair: Dr. David McConkey

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta “Monty” Pal

## Cancer Control

Liaison: Dr. Peter J. Van Veldhuizen

## Active Studies

**S1600**, “A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes.” Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

**S1823**, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors”, PI: Craig Nichols– Activated 6/1/2020 GU Champions: Thomas Frye & Anishka D’Souza

**S1931** (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

**S1937** (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1

Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937

## Diverse Studies of Interest

**S1609**, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

**CTSU/A031702**, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

**CTSU/EAY 131**, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol Z1G reactivated: 2/23/22

**CTSU/EA8134**, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	6	-	1	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	2	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	6	-
Cancer Research Consortium of West Michigan NCORP	2	5	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	6	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	9	2	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	1	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	3	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	1	-	-	-	-	-	-	-
Desert Regional Medical Center	1	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	17	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	75	66	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	3	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	8	8	1	-	3	1	-	1	-
Henry Ford Hospital	23	4	-	1	-	-	-	-	2
Instituto Nacional De Cancerologia	1	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	1	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	16	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	6
Loyola University Medical Center	9	5	1	2	-	-	-	-	1
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	5	-	-	1	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	7	18	-	2	-	1	-	-	-
Montana Cancer Consortium NCORP	3	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	10	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	1
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-
Northwestern University LAPS	-	8	1	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702
Ohio State University Comprehensive Cancer Center LAPS	2	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	1	-	-	-	1	-	-	4
SCL Health Saint Joseph Hospital	2	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	8	1	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-
Tulane University Health Sciences Center	-	-	9	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	12	9	2	3	-	-	-	9	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	4	6	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	3	3	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	2	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	-	3	-	-	12	-	4
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	-	2	-	-	-	-	-	1
University of Arkansas for Medical Sciences	2	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	5	3	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	4	5	-	3	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	7	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	3	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	13	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	-	-	-	-	1
University of Oklahoma Health Sciences Center LAPS	27	15	4	-	-	1	-	-	-
University of Rochester LAPS	23	-	1	-	-	-	-	-	3
University of Texas Health Science Center at San Antonio	7	-	2	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	79	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	1	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	2	2	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	3	4	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	1	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	10	6	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	3	-	-	-	-	-	-	-
ALLIANCE	95	27	3	1	-	-	-	-	-
ECOG-ACRIN	78	34	6	2	1	-	-	-	-
NRG	84	118	6	1	-	-	-	-	-
<b>Total</b>	<b>696</b>	<b>411</b>	<b>63</b>	<b>23</b>	<b>5</b>	<b>4</b>	<b>12</b>	<b>16</b>	<b>24</b>

## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A031704	A031801	A031803	A031901	A031902	A032001	A032101	EA8134	EA8171
Ascension Providence Hospitals - Southfield	2	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	1	-	-	-	-	-	46
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	4	6	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	14	-	-	-	-	-	11
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	2
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	6	-	-	2	-	-	-	-	1
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	56	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	1	-	-	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	1	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	1	-	-	-	-	-	-	-	-
Northwestern University LAPS	2	-	-	-	-	-	1	-	-

## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	A031704	A031801	A031803	A031901	A031902	A032001	A032101	EA8134	EA8171
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	5	-	-	-	-	-	-	-	12
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-
Tulane University Health Sciences Center	1	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	3	7	5	-	-	2	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	9	-
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	1	7	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	5	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	11	-	-	-	-	-	1	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	7	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	6	-	-	-	-	-	13
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
<b>Total</b>	<b>110</b>	<b>10</b>	<b>36</b>	<b>2</b>	<b>5</b>	<b>8</b>	<b>2</b>	<b>10</b>	<b>85</b>



## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA8183	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU005	NRGGU008
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	2	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	11	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	25	1	1	4
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	1	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	1	-
Northwell Health NCORP	-	-	-	-	-	-	-	1
Northwestern University LAPS	-	-	-	-	-	-	-	-

## Genitourinary Committee

Accrual from trial opening through 6/30/2023 by Institution and Study

	EA8183	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU005	NRGGU008
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	5	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	2	-
Tulane University Health Sciences Center	-	-	-	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	1
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
U of Alabama at Birmingham/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	-	1	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	2	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	3	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	1	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-
<b>Total</b>	<b>4</b>	<b>1</b>	<b>19</b>	<b>2</b>	<b>28</b>	<b>4</b>	<b>9</b>	<b>7</b>

## Genitourinary Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGU009	NRGGU010	NRGGU011
Ascension Providence Hospitals - Southfield	-	-	-
Audie L Murphy VA Hospital	-	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	9	-	1
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Instituto Nacional De Cancerologia	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loyola University Medical Center	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Mercy Medical Center - Des Moines	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-
New Mexico Minority Underserved NCORP	-	-	-
Northwell Health NCORP	2	1	-

## Genitourinary Committee

### Accrual from trial opening through 6/30/2023 by Institution and Study

	NRGGU009	NRGGU010	NRGGU011
Northwestern University LAPS	-	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	-
SCL Health Saint Joseph Hospital	-	3	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	-	-	-
Tulane University Health Sciences Center	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-
University of Colorado Cancer Center LAPS	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	1	-
University of Mississippi Medical Center	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	2	-
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Virginia Mason Medical Center	3	2	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-
Western States Cancer Research NCORP	1	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
<b>Total</b>	<b>17</b>	<b>13</b>	<b>1</b>